COMMUNIQUÉS West-GlobeNewswire

Mentions légales

* Temps de fermeture de l’ulcère avec HydroTac® : moins de 15 semaines alors que les données de la littérature montrent que 40-60% des ulcères nécessitent 20 à 24 semaines pour cicatriser. (1) Mikosiński, J. et al. Clinical assessment of a foam dressing containing growth factor-enhancing hydrated polyurethanes. J Wound Care.2018;27(9):608-18. HydroTac® : DM de classe IIb – Fabricant : PAUL HARTMANN AG – Organisme notifié : CE 0123. Lire attentivement les instructions figurant dans la notice (et/ou sur l’étiquetage). Remboursé par les organismes d’assurance maladie : consultez les modalités sur le site www.ameli.fr. Réf : 14122018. Date de création : Décembre 2018

Néovacs présente les résultats précliniques de son candidat vaccin thérapeutique IL-4 / IL-13 Kinoïde au Congrès Keystone
21/03/2019 - 07:30
COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE NÉOVACS PRÉSENTE LES RESULTATS PR É CLINIQUES DE SON CANDIDAT VACCIN TH É RAPEUTIQUE IL-4/IL-13 KINO Ϊ DE AU CONGRÈS KEYSTONE : « Origines des maladies [...]
Neovacs to present the preclinical results of its therapeutic vaccine candidate IL-4 / IL-13 Kinoid at Keystone Congress
21/03/2019 - 07:30
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS TO PRESENT THE PRECLINICAL RESULTS OF ITS THERAPEUTIC VACCINE CANDIDATE IL-4 / IL-13 KINOID AT KEYSTONE CONGRESS: “Origins of Allergic Disease: Microbial, Epithelial [...]
Bavarian Nordic Awards Restricted Stock Units to Executive Management
21/03/2019 - 07:58
COPENHAGEN, Denmark, March 21, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company has awarded restricted stock units to members of the Executive Management. The Board of Directors of [...]
Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director
21/03/2019 - 08:00
LONDON, March 21, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]
New Board starts reviewing the situation in Oasmia
21/03/2019 - 08:30
March 19th, the Extra General Meeting in Oasmia elected a new Board on the initiative of the main owner Arwidsro. The EGM was well represented with over a hundred participating shareholders and over 400 proxies. Jörgen [...]
Establishment Labs Reports Fourth Quarter and Full Year 2018 Financial Results
20/03/2019 - 21:01
NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today [...]
BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering
20/03/2019 - 21:05
BERKELEY, Calif. and VANCOUVER, British Columbia, March 20, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company [...]
Corcept Therapeutics Announces Poster Presentations at the 2019 Annual Meeting of the Endocrine Society Meeting
20/03/2019 - 21:05
MENLO PARK, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic [...]
Sharecare announces winners of inaugural Sharecare Awards
20/03/2019 - 21:16
ATLANTA, March 20, 2019 (GLOBE NEWSWIRE) -- Sharecare, the digital health company that helps people manage all their health in one place, has announced the recipients of its first-ever Sharecare Awards , which recognize [...]
Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2019
20/03/2019 - 21:20
BERKELEY, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology [...]
Sientra® Issues Statement in Response to FDA Post-Approval Study Warning Letter
20/03/2019 - 21:26
Provides Initial Response to FDA SANTA BARBARA, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company (“Sientra" or the “Company”), today announced it has provided an [...]
Rockwell Medical, Inc. to Present at Sidoti & Company LLC Spring 2019 Investor Conference
20/03/2019 - 21:30
WIXOM, Mich., March 20, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, will present at the Sidoti & [...]
Kane Biotech Schedules Full Year 2018 Earnings Conference Call and Business Update
20/03/2019 - 21:30
Conference Call to be held Tuesday, March 26 at 4:00pm ET WINNIPEG, Manitoba, March 20, 2019 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane Biotech”), is pleased to announce today that it [...]
PROJECT HOPE RESPONDS TO DEADLY MOZAMBIQUE CYCLONE
20/03/2019 - 21:52
“Cyclone Idai was deadly. If we don’t act now, the aftermath will be deadlier.” Millwood, Virginia, March 20, 2019 (GLOBE NEWSWIRE) -- Project HOPE is on the ground in Mozambique working as quickly as possible to gather [...]
Portola Pharmaceuticals’ Co-Founder Dr. Charles Homcy Retires from the Company’s Board of Directors
20/03/2019 - 22:00
SOUTH SAN FRANCISCO, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that on March 15, 2019 Charles Homcy, M.D., informed the Board of his decision to retire [...]
Galapagos increases share capital through warrant exercises
20/03/2019 - 22:02
Mechelen, Belgium; 20 March 2019, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 149,370 new ordinary [...]
NOTICE TO CONVENE ORDINARY GENERAL MEETING
20/03/2019 - 22:11
INDKALDELSE TIL ORDINÆR GENERALFORSAMLING NOTICE TO CONVENE ORDINARY GENERAL MEETING KALLELSE TILL ÅRSSTÄMMA Der indkaldes herved til ordinær generalforsamling i Oncology Venture A/S (“ Selskabet “): Notice is hereby [...]
MatriSys Bioscience announces successful FDA Pre-IND review and Phase 2 plans for MSB-01, a revolutionary human-microbiome based treatment for Atopic Dermatitis
21/03/2019 - 00:55
SAN DIEGO, March 20, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a clinical stage biotechnology company developing rationally designed microbiome therapeutics to treat the top five skin diseases, today announced [...]
Genomics England and Cambridge Cancer Genomics (CCG.ai) announce immunotherapy partnership
21/03/2019 - 01:00
Partnership announced to improve access to, and the effectiveness of, immunotherapies in lung and colorectal cancers CAMBRIDGE, United Kingdom, March 20, 2019 (GLOBE NEWSWIRE) -- Genomics England, the Department of [...]

COMMUNIQUÉS West-GlobeNewswire

Pages